Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis

Drug Metabolism and Disposition

Volumn 42, Issue 2, 2014, Pages 201-206

  Laizure, S Casey ^a   Parker, Robert B ^a   Herring, Vanessa L ^a   Hu, Zhe Yi ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BIS(4 NITROPHENYL) PHOSPHATE; CARBAMIC ACID ESTER; CARBOXYLESTERASE; COCAINE; DABIGATRAN ETEXILATE; DRUG METABOLITE; ESTER DERIVATIVE; RECOMBINANT ENZYME;

ARTICLE; CONTROLLED STUDY; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG TRANSFORMATION; IN VITRO STUDY; LIVER CELL; MICROSOME; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANTITHROMBINS; BENZIMIDAZOLES; BIOTRANSFORMATION; CARBOXYLESTERASE; CARBOXYLIC ESTER HYDROLASES; COCAINE; ENZYME INHIBITORS; HUMANS; HYDROLYSIS; INTESTINES; KINETICS; LIVER; MICROSOMES, LIVER; PRODRUGS; PYRIDINES; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

EID: 84891775301     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.054353     Document Type: Article

References (29)

1. Bell GH, Novak AJ, Griffin WC, 3rd, and Patrick KS (2011) Transdermal and oral dlmethylphenidate- ethanol interactions in C57BL/6J mice: transesterification to ethylphenidate and elevation of d-methylphenidate concentrations. J Pharm Sci 100:2966-2978.
2. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, and Roth W (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36: 386-399. (Pubitemid 351185753)
3. Bourland JA, Martin DK, and Mayersohn M (1997) Carboxylesterase-mediated transesterification of meperidine (Demerol) and methylphenidate (Ritalin) in the presence of [2H6]ethanol: preliminary in vitro findings using a rat liver preparation. J Pharm Sci 86:1494-1496. (Pubitemid 28018334)
4. Brzezinski MR, Spink BJ, Dean RA, Berkman CE, Cashman JR, and Bosron WF (1997) Human liver carboxylesterase hCE-1: binding specificity for cocaine, heroin, and their metabolites and analogs. Drug Metab Dispos 25:1089-1096. (Pubitemid 27396498)
5. Cami J, Farré M, González ML, Segura J, and de la Torre R (1998) Cocaine metabolism in humans after use of alcohol. Clinical and research implications. Recent Dev Alcohol 14:437-455.
6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, and Varrone J, et al.; RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151.
7. Farré M, de la Torre R, González ML, Terán MT, Roset PN, Menoyo E, and Camí J (1997) Cocaine and alcohol interactions in humans: neuroendocrine effects and cocaethylene metabolism. J Pharmacol Exp Ther 283:164-176. (Pubitemid 27438959)
8. Harper P, Young L, and Merriman E (2012) Bleeding risk with dabigatran in the frail elderly. N Engl J Med 366:864-866.
9. Hu Z, Sun Y, Du F, Niu W, Xu F, Huang Y, and Li C (2011) Accurate determination of the anticancer prodrug simmitecan and its active metabolite chimmitecan in various plasma samples based on immediate deactivation of blood carboxylesterases. J Chromatogr A 1218: 6646-6653.
10. Hu ZY, Parker RB, Herring VL, and Laizure SC (2013) Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem 405:1695-1704.
11. Imai T (2006) Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab Pharmacokinet 21:173-185.
12. Imai T, Taketani M, Shii M, Hosokawa M, and Chiba K (2006) Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab Dispos 34:1734-1741. (Pubitemid 44427476)
13. Imai T and Ohura K (2010) The role of intestinal carboxylesterase in the oral absorption of prodrugs. Curr Drug Metab 11:793-805.
14. Laizure SC, Mandrell T, Gades NM, and Parker RB (2003) Cocaethylene metabolism and interaction with cocaine and ethanol: role of carboxylesterases. Drug Metab Dispos 31:16-20. (Pubitemid 36735253)
15. Laizure SC, Herring V, Hu Z, Witbrodt K, and Parker RB (2013) The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy 33: 210-222.
16. Parker RB and Laizure SC (2010) The effect of ethanol on oral cocaine pharmacokinetics reveals an unrecognized class of ethanol-mediated drug interactions. Drug Metab Dispos 38:317-322.
17. Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, Malcolm R, Janis GC, and Markowitz JS (2007) Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 81:346-353. (Pubitemid 46364487)
18. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, and Wallentin L (2013) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients in the RE-LY Trial [published online ahead of print September 26, 2013]. J Am Coll Cardiol doi: 10.1016/j.jacc.2013.07.104.
19. Rhoades JA, Peterson YK, Zhu HJ, Appel DI, Peloquin CA, and Markowitz JS (2012) Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions. Pharm Res 29:972-982.
20. Roberts SM, Harbison RD, and James RC (1993) Inhibition by ethanol of the metabolism of cocaine to benzoylecgonine and ecgonine methyl ester in mouse and human liver. Drug Metab Dispos 21:537-541. (Pubitemid 23154215)
21. Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, and La Du BN (2002) Current progress on esterases: from molecular structure to function. Drug Metab Dispos 30:488-493. (Pubitemid 34456967)
22. Song N, Parker RB, and Laizure SC (1999) Cocaethylene formation in rat, dog, and human hepatic microsomes. Life Sci 64:2101-2108. (Pubitemid 29236570)
23. Stangier J (2008) Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 47:285-295. (Pubitemid 351508116)
24. Stangier J, Rathgen K, Stähle H, Gansser D, and Roth W (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64:292-303. (Pubitemid 47283865)
25. Stangier J, Stähle H, Rathgen K, Roth W, and Shakeri-Nejad K (2008) Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 48:1411-1419.
26. Takahashi S, Katoh M, Saitoh T, Nakajima M, and Yokoi T (2009) Different inhibitory effects in rat and human carboxylesterases. Drug Metab Dispos 37:956-961.
27. Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse EL, Black C, Yang D, Shi D, and Yan B (2006) Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 319:1467-1476.
28. Umulis DM, Gürmen NM, Singh P, and Fogler HS (2005) A physiologically based model for ethanol and acetaldehyde metabolism in human beings. Alcohol 35:3-12. (Pubitemid 40726306)
29. Zhu HJ, Appel DI, Peterson YK, Wang Z, and Markowitz JS (2010) Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions. Toxicology 270:59-65.